Healthcare & Medical Devices Global On demand · 24-48h

Global Neuromodulation and Neurostimulation Pain Management Devices Market Strategic Research Report

Global Neuromodulation and Neurostimulation Pain Management …
$3,500 USD
Market Research Reports
Strategic Research Report
Global Neuromodulation and Neurostimulation Pain Management Devices Market
$2.34B2025
6.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Spinal Cord Stimulators, Transcutaneous Electrical Nerve Stimulation (TENS) Devices

By Application: Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Medtronic Plc, Boston Scientific Corporation, Pfizer Inc. (Hospira Inc.), Johnson & Johnson (Codman And Shurtleff, Inc.), Stryker Corporation, Kimberly-Clark Corporation (Baylis Medical), Colfax Corporation (Djo Global Llc), Abbott Laboratories, B Braun Melsungen Ag, Baxter International Inc.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 94 pages
Market size 2025
$2.34B
Billion USD
Forecast CAGR
6.7%
2025-2032
Forecast 2032
$3.7B
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Neuromodulation and Neurostimulation Pain Management Devices market size is predicted to grow from US$ 2,344 million in 2025 to US$ 3,655 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.

Pain management is a branch of medical science, which eases the suffering of patients who suffer from chronic pain. Acute pain has sudden onset of action, whereas chronic pain persists for a longer duration, which leads to need for its management. Neuromodulation and Neurostimulation Pain Management Devices are medical devices that are used in management of different types of pain such as neuropathic pain, cancer pain, Facial & Migraine Pain, Musculoskeletal Pain, and others.

Spinal cord stimulators, transcutaneous electrical nerve stimulation devices, analgesic infusion pumps, and ablation devices are various types of pain management devices available in the market. The growth of the global pain management devices market is driven by increase in geriatric population, rise in prevalence of chronic pain, surge in geriatric population, surge in awareness among people toward pain management devices, improved R&D investment to develop innovative products, and launch of innovative products. In addition, increase in demand for pain management devices among the developing countries and rise in adoption of pain management devices for management of chronic pain are other factors that contribute toward the growth of the market. Furthermore, untapped potential offered by developing economies present lucrative opportunities for market expansion during the forecast period. However, hypersensitivity reactions and post-operative infections caused due to use of these devices limit their adoption, which hampers the growth of the market. Moreover, these devices are usually used as second line of treatment in patients with chronic pain who become resistant to drug therapy, which limits the growth of the global pain management devices market.

This report presents a comprehensive overview of the global Neuromodulation and Neurostimulation Pain Management Devices market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Spinal Cord Stimulators
  • Transcutaneous Electrical Nerve Stimulation (TENS) Devices

Segment by Application

  • Neuropathic Pain
  • Cancer Pain
  • Facial & Migraine Pain
  • Musculoskeletal Pain
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Neuromodulation and Neurostimulation Pain Management Devices market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Neuropathic Pain, Cancer Pain, Facial & Migraine Pain evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Neuromodulation and Neurostimulation Pain Management Devices Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$2.34B
2025
Forecast
$3.7B
2032
CAGR
6.7%
2025–2032
Regionen
5
global
Key companies
Medtronic PlcBoston Scientific CorporationPfizer Inc. (Hospira Inc.)Johnson & Johnson (Codman And ShurtleffInc.)Stryker CorporationKimberly-Clark Corporation (Baylis Medical)Colfax Corporation (Djo Global Llc)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Spinal Cord StimulatorsTranscutaneous Electrical Nerve Stimulation (TENS) Devices
By Application
Neuropathic PainCancer PainFacial & Migraine PainMusculoskeletal PainOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Spinal Cord Stimulators
  • 3.1.3 Transcutaneous Electrical Nerve Stimulation (TENS) Devices
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Neuropathic Pain
  • 4.1.3 Cancer Pain
  • 4.1.4 Facial & Migraine Pain
  • 4.1.5 Musculoskeletal Pain
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Medtronic Plc
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Boston Scientific Corporation
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Pfizer Inc. (Hospira Inc.)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Johnson & Johnson (Codman And Shurtleff, Inc.)
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Stryker Corporation
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Kimberly-Clark Corporation (Baylis Medical)
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Colfax Corporation (Djo Global Llc)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Abbott Laboratories
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 B Braun Melsungen Ag
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Baxter International Inc.
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Neuromodulation and Neurostimulation Pain Management Devices market?
The global Neuromodulation and Neurostimulation Pain Management Devices market is estimated at US$ 2.34 billion in 2025 (base year) and is projected to reach US$ 3.65 billion by 2032.
How fast is the Neuromodulation and Neurostimulation Pain Management Devices market expected to grow?
The market is expected to grow at a CAGR of 6.7% from 2026 to 2032, expanding from US$ 2.34 billion in 2025 to US$ 3.65 billion in 2032, roughly 1.6 times its base-year value.
What does the Neuromodulation and Neurostimulation Pain Management Devices market cover?
Pain management is a branch of medical science, which eases the suffering of patients who suffer from chronic pain. Acute pain has sudden onset of action, whereas chronic pain persists for a longer duration, which leads to need for its management. Neuromodulation and Neurostimulation Pain Management Devices are medical devices that are used in management of different types of pain such as neuropathic pain, cancer pain, Facial & Migraine Pain, Musculoskeletal Pain, and others.
How is the Neuromodulation and Neurostimulation Pain Management Devices market segmented by type?
By type, the market is segmented into Spinal Cord Stimulators and Transcutaneous Electrical Nerve Stimulation (TENS) Devices.
What are the key applications of Neuromodulation and Neurostimulation Pain Management Devices?
Key applications covered include Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain and Others.
Which companies are profiled in the Neuromodulation and Neurostimulation Pain Management Devices market report?
Key players profiled include Medtronic Plc, Boston Scientific Corporation, Pfizer Inc. (Hospira Inc.), Johnson & Johnson (Codman And Shurtleff, Inc.), Stryker Corporation, Kimberly-Clark Corporation (Baylis Medical), Colfax Corporation (Djo Global Llc) and Abbott Laboratories, among 10 companies covered in total.
What geographies does the Neuromodulation and Neurostimulation Pain Management Devices market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Neuromodulation and Neurostimulation Pain Management Devices?
The growth of the global pain management devices market is driven by increase in geriatric population, rise in prevalence of chronic pain, surge in geriatric population, surge in awareness among people toward pain management devices, improved R&D investment to develop innovative products, and launch of innovative products.
Who should buy the Neuromodulation and Neurostimulation Pain Management Devices market report?
The report is intended for manufacturers and solution providers, distributors and end users in Neuropathic Pain, Cancer Pain and Facial & Migraine Pain, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Neuromodulation and Neurostimulation Pain Management Devices market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.